Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2021-10-14 Major Shareholding Noti…
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Otrzymanie zawiadomień, o którym mowa w art. 19 ust. 1 MAR - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is very short (796 characters) and discusses transactions involving shares of the company by entities closely associated with a member of the management/supervisory board (Pan Robert Przytuła, Przewodniczącym Rady Nadzorczej). The text explicitly mentions receiving two notifications under Article 19 of the MAR Regulation (Regulation on Insider Dealing and Market Abuse), which typically concerns transactions by Persons Discharging Managerial Responsibilities (PDMRs) or their closely associated persons. This directly corresponds to insider trading or director's dealing disclosures. The filing category 'Director's Dealing (DIRS)' fits this description best, as it covers reports of personal share transactions by directors and executives (insider trades). Although it mentions the notifications are attached, the core content is the disclosure of the transaction itself, making DIRS more specific than RPA or RNS.
2021-10-14 Polish
Zawarcie umowy warrantowej i dalsze działania dotyczące finansowania od EBI - Content (PL)
Share Issue/Capital Change Classification · 99% confidence The document text, written in Polish, details the signing of a warrant agreement ("Umowa Warrantowa") between the company (Scope Fluidics S.A.) and the European Investment Bank (EBI). This agreement involves the issuance of 126,576 subscription warrants to EBI, which grant the right to acquire shares at a nominal price. This action directly relates to financing activities, capital structure changes, and the issuance of financial instruments (warrants) tied to a prior financing agreement. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions future reports, the core content is the announcement of the financing agreement itself, not just the announcement of a report.
2021-10-07 Polish
Wyniki przedrejestracyjnych testów walidacyjnych systemu BacterOMIC - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Management Board of Scope Fluidics S.A. regarding the successful validation of pre-registration tests for their BacterOMIC system, which is a diagnostic product. It details the results (90% agreement with reference methods for 20 antibiotics) and outlines the next steps: filing an application with the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) to obtain CE-IVD marking, which grants the right to market the system in the EU. This content relates to product development, regulatory compliance, and future market entry plans for a medical device. It is not a full annual report (10-K), an earnings release (ER), a management discussion/analysis (MDA), or a general regulatory filing (RNS). It is a specific update on a product's regulatory pathway and testing results, which aligns best with a general regulatory announcement or a specific update on product/legal matters. Given the focus on regulatory steps (URPL application, CE-IVD marking) and product validation, it is a significant regulatory/product update. Since there is no specific code for 'Product Regulatory Update,' and it is not a legal proceeding (LTR), the most appropriate general category for a significant, non-financial, non-management change announcement that is regulatory in nature is 'Regulatory Filings' (RNS), or potentially 'Capital/Financing Update' (CAP) if it were related to funding, which it is not directly. However, since it details the progress towards obtaining market authorization for a medical device, it is a crucial piece of information for investors regarding the company's core operations and compliance. Given the options, and that it is a formal announcement of a significant operational/regulatory milestone, RNS serves as the best fit for a non-standard, important regulatory update that isn't a standard financial report or management change.
2021-09-30 Polish
Zawiadomienie z art. 69 ustawy o ofercie publicznej od ESALIENS TFI S.A.
Major Shareholding Notification Classification · 98% confidence The document is a formal notification titled "ZAWIADOMIENIE O ZMIANIE STANU POSIADANEGO UDZIAŁU W OGÓLNEJ LICZBIE GŁOSOW W SPÓŁCE" (Notification of a change in the holding of shares in the total number of votes in the company). It details the change in shareholding percentage (from 5.00% to 4.99%) of several investment funds managed by Esaliens TFI S.A. in Scope Fluidics S.A. This type of filing, reporting changes in significant share ownership thresholds, directly corresponds to the Major Shareholding Notification category. The document length is short (2573 chars), but its content is a specific regulatory disclosure, not just an announcement of a report, making it a direct filing type.
2021-09-30 Polish
Zawiadomienie o zmianie stanu posiadania akcji Spółki - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is very short (184 characters) and states that the Management Board ('Zarząd') received a notification from ESALIENS TFI S.A. regarding Article 69 of the Public Offering Act ('ustawy o ofercie publicznej') and refers to the content being in an attached file ('jak w załączonym pliku'). This structure—a brief announcement referencing an attached document—strongly suggests a notification of a significant event or filing, rather than the full report itself. Article 69 typically relates to changes in major shareholdings. Since the document is an announcement referencing an attachment about a change in major shareholding, it fits best under Major Shareholding Notification (MRQ) if the content is about crossing a threshold, or as a general Regulatory Filing (RNS) if it's a mandatory disclosure that doesn't fit other specific categories. Given the reference to 'art. 69 ustawy o ofercie publicznej' (which governs major shareholding notifications), MRQ is the most specific fit, but because the text is just an announcement of receipt/publication of the notification content (following the 'MENU VS MEAL' rule), and it's a regulatory disclosure, RNS is a safer general classification if MRQ is reserved for the actual filing document. However, since the content *is* about a major shareholding change notification, MRQ is the intended subject matter. Given the brevity and the 'announcement of attached file' structure, I will classify it as RNS (Regulatory Filing) as the most appropriate fallback for a short announcement referencing an attached regulatory document, although MRQ is the underlying subject matter. Re-evaluating: The content describes receiving a notification about a major shareholding change (Art. 69). This is precisely what MRQ covers. Since this is a short announcement *about* the filing, RNS is technically correct by the 'MENU VS MEAL' rule, but MRQ is the specific regulatory event. I will use RNS as the document is clearly an announcement of a filing/information, not the filing itself, adhering strictly to Rule 2.
2021-09-30 Polish
Opis poszczególnych działań w ramach projektów
Regulatory Filings Classification · 95% confidence The document is titled "Informacja dotycząca dalszych działań w ramach projektu PCR|ONE oraz projektu BacterOMIC – załącznik do raportu bieżącego nr 30/2021" (Information regarding further actions within the PCR|ONE project and the BacterOMIC project – attachment to current report no. 30/2021). The content details future R&D plans, certification processes (CE-IVD, IVDR), scaling up production, and implementing an Early Access Program (PEA) for two distinct projects (PCR|ONE and BacterOMIC). This structure—providing detailed operational and strategic updates following a specific reporting period (Q4 2021 – Q3 2022)—is characteristic of a comprehensive management discussion or a detailed update accompanying a mandatory periodic filing. Since it is an attachment to a 'raport bieżący' (current report), and it provides extensive management commentary on business trends, R&D progress, and future outlook, it aligns best with the Management Discussion and Analysis (MDA) category, which covers management's explanation of financial results, business trends, and outlook. It is not a full Annual Report (10-K), an Earnings Release (ER) (which is usually just highlights), or a simple Regulatory Filing (RNS) because it contains substantial, specific management analysis rather than just a brief announcement.
2021-09-27 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.